High-Throughput 3D Screening: Accelerating Drug Discovery in the NAMs Era
With FDA actively mandating the shift toward NAMs and OoC models, the pressure to move new 3D biology from benchtop to high-throughput pipeline has never been greater.
Following our highly successful Vol. 3 session on NAMs and cancer research, OpenFlow returns to tackle the industry’s most significant bottleneck: Scale.
For Vol. 4, we are honored to host a masterclass led by a true titan of biofabrication, Prof. Shaochen Chen (Zable Endowed Chair at UC San Diego). Prof. Chen is a pioneer who bridges academic excellence with massive commercial success—from a $25M exit with his previous venture to a recent $26M ARPA-H award to bioprint functional human livers. He brings that same commercial drive to his new startup, TissueGenix, Inc.
On May 21st, we will demonstrate two complementary paths to finally cracking the High-Throughput Screening (HTS) code for 3D drug discovery — and building the scalable NAMs-ready pipeline that FDA is pushing the industry toward.
Event Agenda
4:00 PM | Registration & Welcome
Check-in and opening remarks by the HiComp Team.
4:30 PM – 5:10 PM | Keynote Session I
Rapid Bioprinting of Micro-tissues in Standard Well Plates for High Throughput Drug Testing
Speaker:
Dr. Shaochen Chen (Endowed Chair Professor at UCSD and co-Founder of TissueGenix, Inc)
Dr. Zack Zhong (VP of R&D, TissueGenix, Inc)
5:20 PM – 6:00 PM | Keynote Session 2
Scaling 3D Discovery: Custom Microplates for High-Throughput Screening
Speaker: Dr. Jing Chen (Founder, CEO of HiComp）
6:00 PM – 7:30 PM | The OpenFlow Happy Hour
Pizza, wings, drinks, and networking
⚠️ Important Note & Registration Policy: To maintain the depth and quality of our technical discussions, space is strictly limited. NO WALK-INS will be accepted. All guests must be pre-registered and confirmed via Luma prior to arrival.
May the flow be with you!